Protecting bone in long-term HIV positive patients receiving antiretrovirals

Reference

• Rockstroh JK. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals. Liver Int. 2015;35(Suppl 1):51–55.
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. Aids. 2007;21(5):617–623.
   PubMed Web of Science ®Google Scholar
• Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60(8):1242–1251.
   PubMed Web of Science ®Google Scholar
• Weitzmann MN T-cells and B-cells in osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):461–467.
   PubMed Web of Science ®Google Scholar
• Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499–3504.
   PubMed Web of Science ®Google Scholar
• Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Aids. 2000;14(4):F63–67.
   PubMed Web of Science ®Google Scholar
• Short CE, Shaw SG, Fisher MJ, et al. Prevalence of and risk factors for osteoporosis and fracture among a male HIV-infected population in the UK. Int J STD AIDS. 2014;25(2):113–121.
   PubMed Web of Science ®Google Scholar
• Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12(10):1198–1202.
   PubMed Web of Science ®Google Scholar
• Negredo E, Domingo P, Perez-Alvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother. 2014;69(12):3368–3371.
   PubMed Web of Science ®Google Scholar
• Yin MT, Modarresi R, Shane E, et al. Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporosis Int. 2011;22(5):1459–1468.
   PubMed Web of Science ®Google Scholar
• Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;(7): CD000333. doi:10.1002/14651858.CD000333. pub2.
   Web of Science ®Google Scholar
• Kawai T, Matsuyama T, Hosokawa Y, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006;169(3):987–998.
   PubMed Web of Science ®Google Scholar
• Adeyemi OM, Agniel D, French AL, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr. 2011;57(3):197–204.
   PubMed Web of Science ®Google Scholar
• Cotter EJ, Malizia AP, Chew N, et al. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses. 2007;23(12):1521–1530.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in hiv-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–580.
   PubMed Web of Science ®Google Scholar
• Santos WR, Santos WR, Paes PP et al. Impact of strength training on bone mineral density in patients infected with hiv exhibiting lipodystrophy. J Strength Conditioning Res/Nat Strength Conditioning Assoc. 2015;29:3466–3471.
   PubMed Web of Science ®Google Scholar
• EACS. EACS HIV treatment guidelines. 2014. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000;106(10):1229–1237.
   PubMed Web of Science ®Google Scholar
• Peters BS, Perry M, Wierzbicki AS, et al. A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. Plos One. 2013;8(10):e78048.
   PubMed Web of Science ®Google Scholar
• Gruber MF, Weih KA, Boone EJ, et al. Endogenous macrophage CSF production is associated with viral replication in HIV-1-infected human monocyte-derived macrophages. J Immunology. 1995;154(10):5528–5535.
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. Plos One. 2014;9(8):e106221.
   PubMed Web of Science ®Google Scholar
• Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. Aids. 2003;17(7):971–979.
   PubMed Web of Science ®Google Scholar
• Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62(11):1279–1286.
   PubMed Web of Science ®Google Scholar
• Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int. 1992;2(6):285–289.
   PubMed Web of Science ®Google Scholar
• Young B, Dao CN, Buchacz K, et al., Investigators HIVOS. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52(8):1061–1068.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Schrack JA, Jankowski CM, et al. Functional impairment, disability, and frailty in adults aging with HIV-infection. Curr HIV/AIDS Rep. 2014;11(3):279–290.
   PubMed Web of Science ®Google Scholar
• Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350–354.
   PubMed Web of Science ®Google Scholar
• Bachmann KN, Bruno AG, Bredella MA, et al. Vertebral strength and estimated fracture risk across the bmi spectrum in women. J Bone Miner Res. 2016;31(2):281–288.
   PubMed Web of Science ®Google Scholar
• Escota GV, Mondy K, Bush T et al. High prevalence of low bone mineral density and substantial bone loss over 4 years among hiv-infected persons in the era of modern antiretroviral therapy. AIDS Res Hum Retroviruses. 2016;32(1):59–67.
   PubMed Web of Science ®Google Scholar
• Pinto Neto LF, Ragi-Eis S, Vieira NF, et al. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. J Clin Densitometry. 2011;14(4),434–439.
   PubMed Web of Science ®Google Scholar
• May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Aids. 2014;28(8):1193–1202.
   PubMed Web of Science ®Google Scholar
• Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482–490.
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Moreno S, Cacopardo B, et al. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis. AIDS Rev. 2014;16(4):213–222.
   PubMed Web of Science ®Google Scholar
• Negredo E, Diez-Perez A, Bonjoch A, et al. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J Antimicrob Chemother. 2015;70(7):2104–2107.
   PubMed Web of Science ®Google Scholar
• Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis. 2012;205(Suppl 3):S391–398.
   PubMed Web of Science ®Google Scholar
• Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8):1797–1805.
   PubMed Web of Science ®Google Scholar
• Shiau S, Broun EC, Arpadi SM, et al. Incident fractures in HIV-infected individuals: A systematic review and meta-analysis. Aids. 2013:27(12):1949–1957.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama, 2004;292(2):191–201.
   PubMed Web of Science ®Google Scholar
• Carr A, Grund B, Neuhaus J, et al. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl 1):137–146.
   PubMed Web of Science ®Google Scholar
• Callebaut C, Stepan G, Tian Y, et al. In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2015;59(10):5909–5916.
   PubMed Web of Science ®Google Scholar
• Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38(4):426–431.
   PubMed Web of Science ®Google Scholar
• Schuit SC, Van Der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone, 2004:34(1):195–202.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998;93(2):165–176.
   PubMed Web of Science ®Google Scholar
• Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Aids. 2009:23(7):817–824.
   PubMed Web of Science ®Google Scholar
• Natsag J, Kendall MA, Sellmeyer DE, et al., Osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density. HIV Med. 2016;17(3):196–205.
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006;116(5):1186–1194.
   PubMed Web of Science ®Google Scholar
• Ho-Pham LT, Nguyen UD, Nguyen TV Association between lean mass, fat mass, and bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2014;99(1):30–38.
   PubMed Web of Science ®Google Scholar
• Kanis JA Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis Int. 1994;4(6):368–381.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. Aids. 2007;21(18):2473–2482.
   PubMed Web of Science ®Google Scholar
• Cotter EJ, Mallon PW, Doran PP Is PPARgamma a prospective player in HIV-1-associated bone disease? PPAR Res. 2009;2009:421376.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Kitch D, Tierney C, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. Aids. 2013;27(13):2069–2079.
   PubMed Web of Science ®Google Scholar
• Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):396–405.
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Cenci S, Rifas L, et al. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res. 2001;16(2):328–337.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. Aids. 2006;20(17):2165–2174.
   PubMed Web of Science ®Google Scholar
• Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007;109(9):3839–3848.
   PubMed Web of Science ®Google Scholar
• Negredo E, Bonjoch A, Perez-Alvarez N, et al. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years. HIV Med. 2015;16(7):441–448.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther. 2014;19(2):191–200.
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Spiegelman D, Duggan C, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr. 2005;41(3):339–346.
   PubMed Web of Science ®Google Scholar
• Cotter AG, Sabin CA, Simelane S, et al. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. Aids. 2014;28(14):2051–2060.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL Bone resorption by osteoclasts. Science. 2000;289(5484):1504–1508.
   PubMed Web of Science ®Google Scholar
• Womack JA, Goulet JL, Gibert C, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis. 2013;56(10):1498–1504.
   PubMed Web of Science ®Google Scholar
• Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• Calza L, Magistrelli E, Colangeli V, et al. Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir/boosted protease inhibitor to raltegravir plus nevirapine: a pilot study [Internet]. Antivir Ther. 2015. doi:10.3851/IMP2995. [cited 2016 May 16] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26405177 [Epub ahead of print].
   Google Scholar
• Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175–179.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–319.
   PubMed Web of Science ®Google Scholar
• Torti C, Mazziotti G, Soldini PA, et al. High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine. 2012;41(3):512–517.
   PubMed Web of Science ®Google Scholar
• Brown TT, Moser C, Currier JS, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis. 2015;212(8):1241–1249.
   PubMed Web of Science ®Google Scholar
• Wahl DA, Cooper C, Ebeling PR, et al. A global representation of vitamin D status in healthy populations. Arch Osteoporos. 2012;7:155–172.
   PubMedGoogle Scholar
• Conrado T, Miranda-Filho Dde B, Bandeira F. Vitamin D deficiency in HIV-infected individuals: one more risk factor for bone loss and cardiovascular disease? Arq Bras Endocrinol Metabol. 2010;54(2):118–122.
   PubMed Web of Science ®Google Scholar
• Poynten IM, Zablotska I, Grulich AE Considerations regarding antiretroviral chemoprophylaxis in MSM. Curr Opin HIV AIDS. 2012;7(6):549–556.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5):483–486.
   PubMed Web of Science ®Google Scholar
• Kooij KW, Wit FW, Bisschop PH, et al. Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis. 2015;211(4):539–548.
   PubMed Web of Science ®Google Scholar
• Cotter EJ, Chew N, Powderly WG, et al. HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. AIDS Res Hum Retroviruses. 2011;27(2):187–199.
   PubMed Web of Science ®Google Scholar
• Gullberg B, Johnell O, Kanis JA World-wide projections for hip fracture. Osteoporosis Int. 1997;7(5):407–413.
   PubMed Web of Science ®Google Scholar
• Mpalaris V, Anagnostis P, Goulis DG, et al. Complex association between body weight and fracture risk in postmenopausal women. Obes Rev. 2015;16(3):225–233.
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey AB, Gamble GD, et al. CLINICAL Review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92(12):4522–4528.
   PubMed Web of Science ®Google Scholar
• Martin A, Moore C, Mallon PW, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. Aids. 2013;27(15):2403–2411.
   PubMed Web of Science ®Google Scholar
• Bonnet E, Ruidavets JB, Genoux A, et al. Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study. BMC Infect Dis. 2013;13:293.
   PubMed Web of Science ®Google Scholar
• Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. 2003;J Biol Chem. 278(48):48251–48258.
   PubMed Web of Science ®Google Scholar
• Cosman F, De Beur SJ, LeBoff MS et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014;25(10):2359–2381.
   PubMed Web of Science ®Google Scholar
• Sherwood JE, Mesner OC, Weintrob AC, et al. Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. Clin Infect Dis. 2012;55(12):1727–1736.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–429.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Labbato DE, Storer NJ, et al. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. Aids. 2014;28(12):1759–1767.
   PubMed Web of Science ®Google Scholar
• Mallon PW Alendronate for prevention of Antiretroviral Therapy associated bone loss. Available from: https://clinicaltrials.gov/show/NCT02322099
   Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816–2822.
   PubMed Web of Science ®Google Scholar
• Yin MT, Shiau S, Rimland D, et al. Fracture prediction with modified-FRAX in older HIV-infected and uninfected men. J Acquir Immune Defic Syndr. 2016. PMID: 27003493. [Epub ahead of print]
   Web of Science ®Google Scholar
• Vikulina T, Fan X, Yamaguchi M, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010;107(31):13848–13853.
   PubMed Web of Science ®Google Scholar
• Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17(4):118–123.
   PubMedGoogle Scholar
• Bolland MJ, Grey A, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab. 2012;97(6):1922–1928.
   PubMed Web of Science ®Google Scholar
• Overton ET, Chan ES, Brown TT, et al. Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A randomized trial. Ann Intern Med. 2015;162(12):815–824.
   PubMed Web of Science ®Google Scholar
• Foundation NO. America’s bone health: The state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation, (2002). Available from: http://www.nof.org/advocacy/prevalence.
   Google Scholar
• Torring O. Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2015;7(3):88–102.
   PubMed Web of Science ®Google Scholar
• Yin MT, McMahon DJ, Ferris DC, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2010;95(2):620–629.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Department of Health and Human Services. [cited 2016 May 16]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
   Google Scholar
• Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42(7):1014–1020.
   PubMed Web of Science ®Google Scholar
• Haskelberg H, Pocock N, Amin J, et al. Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine. Plos One. 2014;9(4):e94858.
   PubMed Web of Science ®Google Scholar
• Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. Aids. 2015;29(18):2459–2464.
   PubMed Web of Science ®Google Scholar
• Bloch M, Tong WW, Hoy J et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med. 2014;15(6):373–380.
   PubMed Web of Science ®Google Scholar
• Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. Plos One. 2012;7(6):e38377.
   PubMed Web of Science ®Google Scholar
• Assoumou L, Katlama C, Viard JP, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. Aids. 2013;27(15):2425–2430.
   PubMed Web of Science ®Google Scholar
• Porcelli T, Gotti D, Cristiano A, et al. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporosis Int. 2014;25(9):2263–2269.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523–529.
   PubMed Web of Science ®Google Scholar
• Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–666.
   PubMed Web of Science ®Google Scholar
• O’Neill TJ, Rivera L, Struchkov V, et al. The effect of HIV-hepatitis C co-infection on bone mineral density and fracture: a meta-analysis. Plos One, 2014;9(7):e101493.
   PubMed Web of Science ®Google Scholar
• Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. Aids. 2009;23(8):1021–1024.
   PubMed Web of Science ®Google Scholar
• Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis Int. 2009;20(2):239–244.
   PubMed Web of Science ®Google Scholar
• Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402(6759):304–309.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5):554–561.
   PubMed Web of Science ®Google Scholar
• Compston J Osteoporosis and fracture risk associated with HIV infection and treatment. Endocrinol Metab Clin North Am. 2014;43(3):769–780.
   PubMed Web of Science ®Google Scholar
• Haskelberg H, Mallon PW, Hoy J, et al. Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy. J Acquir Immune Defic Syndr. 2014;67(2):161–168.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18(7):905–913.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int. 2013;24(1):23–57.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Titanji K, Vikulina T, et al. Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun. 2015;6:8282.
   PubMed Web of Science ®Google Scholar
• Pietschmann P, Mechtcheriakova D, Meshcheryakova A, et al. Immunology of osteoporosis: a mini-review. Gerontology. 2016;62(2):128–137.
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Zhang S, Drechsler H, et al. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Mineral Res. 2013;28(12),2577–2583.
   PubMed Web of Science ®Google Scholar
• Wheeler AL, Tien PC, Grunfeld C, et al. Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review. Aids. 2015;29(2):245–246.
   PubMed Web of Science ®Google Scholar
• HIV surveillance Data. Public Health England. 2014 Available from: https://www.gov.uk/government/statistics/hiv-data-tables
   Google Scholar
• Gutierrez F, Masia M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev. 2011;13(2):109–118.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–1801.
   PubMed Web of Science ®Google Scholar
• Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893–897.
   PubMed Web of Science ®Google Scholar